Introduction

Pneumonia remains a leading cause of global morbidity and mortality, with accurate imaging essential for timely diagnosis and management. Chest computed tomography (CT) surpasses chest radiography in sensitivity and detail, revealing characteristic patterns such as ground-glass opacities (GGO), consolidation, crazy-paving, tree-in-bud, halo, and reverse halo signs across bacterial, viral, and fungal etiologies [1-3]. This review synthesizes evidence on CT findings, scanning protocols (including ultra-low-dose techniques), diagnostic performance (sensitivity typically 95-99%, specificity variable due to overlaps), pediatric applications, complications, and differential diagnosis. Special focus is given to COVID-19: acute patterns (bilateral peripheral GGO), evolution in 2026 Omicron subvariants (milder, more atypical features with less consolidation), and Long COVID sequelae (persistent pulmonary GGO/fibrosis in 30-70% at 6-12 months, declining GGO but stable fibrosis up to 36 months; cardiac inflammation via PET/MRI in ~57% with myocarditis/pericarditis-like changes) [4-6]. Advances in AI-enhanced low-dose CT and multimodal imaging (PET/MRI for inflammation) are discussed. Evidence draws from systematic reviews, meta-analyses, and studies through early 2026. Keywords: chest CT pneumonia patterns, ground-glass opacities COVID-19 CT, bacterial viral fungal pneumonia imaging, sensitivity specificity chest CT pneumonia, low-dose CT protocol pneumonia, SARS-CoV-2 Omicron variants 2026 CT findings, Long COVID pulmonary fibrosis CT, Long COVID cardiac PET MRI inflammation.

Pneumonia, an acute inflammatory condition of the lung parenchyma, is predominantly infectious and ranks among the top causes of death worldwide, with millions of cases annually [1]. Community-acquired pneumonia (CAP) affects adults and children, while hospital- and ventilator-associated forms add complexity. Major pathogens include bacteria (Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus), viruses (influenza, SARS-CoV-2), fungi (Aspergillus spp., Pneumocystis jirovecii), and atypicals (Mycoplasma pneumoniae, Legionella).

Diagnosis relies on a multimodal approach: clinical presentation (fever, cough, dyspnea, pleuritic pain), laboratory markers (leukocytosis, CRP, procalcitonin), microbiology (sputum/PCR), and imaging. Imaging confirms parenchymal involvement, assesses extent/severity, identifies complications (abscess, empyema, necrosis), and guides therapy while differentiating mimics (pulmonary edema, hemorrhage, malignancy) [2].

Chest radiography (CXR) serves as the traditional first-line modality due to low cost, availability, and minimal radiation (effective dose ~0.1 mSv). However, CXR sensitivity is limited (50-70% for confirmed pneumonia), often missing early/subtle or posteriorly located disease, leading to occult pneumonia in 20-50% of clinically suspected cases, especially in immunocompromised or elderly patients [2,3].

Chest CT, particularly high-resolution CT (HRCT), provides superior spatial resolution, multiplanar reconstruction, and thin-slice capability, detecting abnormalities overlooked on CXR in 30-50% of cases [3]. Key CT patterns include:

• Ground-glass opacities (GGO): Hazy increased attenuation without obscuring underlying vessels/bronchi, reflecting partial alveolar filling or interstitial thickening.
• Consolidation: Homogeneous opacity completely obscuring vessels/bronchi, indicating dense alveolar filling.
• Crazy-paving: Superimposed interlobular septal thickening on GGO, resembling irregular paving stones.
• Tree-in-bud: Centrilobular small nodules with branching linear opacities, mimicking budding trees and indicating endobronchial spread.
• Halo sign: GGO surrounding a nodule/mass, often due to hemorrhage or angioinvasion.
• Reverse halo (atoll sign): Central GGO with peripheral consolidation ring, seen in organizing pneumonia or invasive fungal disease.

These patterns offer etiologic clues despite significant overlap [1,3]. The COVID-19 pandemic dramatically increased CT utilization, revealing characteristic bilateral peripheral/multifocal GGO with basal predominance [4]. As of February 2026, Omicron subvariants (e.g., XFG ~53% prevalence) dominate, showing generally milder radiographic severity with more atypical distributions and fewer consolidations compared to earlier strains [5,6].

This review comprehensively examines CT patterns by pathogen, optimized scanning protocols (with radiation dose reduction), diagnostic accuracy, pediatric considerations, complications, differentials, COVID-19-specific evolution (including 2026 variants), and Long COVID cardiopulmonary sequelae (persistent pulmonary abnormalities and cardiac inflammation). Evidence is drawn from systematic reviews, meta-analyses, cohort studies, and consensus statements up to early 2026.

Imaging Modalities in Pneumonia Diagnosis

Chest Radiography (CXR)

CXR detects lobar/segmental consolidation, silhouette sign, pleural effusions, and cavitation affordably and quickly. It remains first-line in resource-limited settings and outpatient care. Limitations include low sensitivity for subtle GGO, early disease, or dependent/posterior lesions, with specificity ~70% due to overlap with non-infectious processes (e.g., atelectasis, edema) [2]. Occult pneumonia (CT-positive, CXR-negative) occurs frequently in immunocompromised hosts or atypical infections [3].

Lung Ultrasound (LUS)

LUS has emerged as a valuable bedside tool, especially in critical care and pediatrics. It identifies subpleural consolidations, B-lines (interstitial syndrome), pleural effusions, and dynamic air bronchograms with sensitivity 90-98% and specificity ~90% for bacterial pneumonia, often outperforming CXR [7]. Advantages include no radiation, real-time assessment, and portability. Limitations include operator dependence and poor penetration in obese patients or deep lesions.

Magnetic Resonance Imaging (MRI)

MRI avoids ionizing radiation and excels in soft-tissue contrast, showing promise in pediatric pneumonia for detailed evaluation without radiation exposure. It detects consolidations, effusions, and lymphadenopathy but is hindered by long scan times, motion artifacts, cost, and limited availability [7].

Chest Computed Tomography (CT)

CT is the reference standard for pulmonary infection imaging. It provides exquisite parenchymal detail, early detection of GGO/consolidation, complication identification (necrosis, abscess, empyema), and alternative diagnosis exclusion (e.g., malignancy, vasculitis). Non-contrast HRCT optimizes interstitial/parenchymal assessment; contrast-enhanced CT (CECT) delineates vascular complications, necrosis, or empyema (split pleura sign) [3].

Chest CT Scanning Protocols for Pneumonia

Standardized protocols balance diagnostic quality with radiation minimization (ALARA principle), especially relevant for serial/follow-up imaging in pandemics or Long COVID [8].

Non-Contrast Chest CT (NCCT)

Preferred for initial parenchymal evaluation.

• Patient positioning: Supine, arms elevated, full inspiratory breath-hold.
• Scan range: Lung apices to costophrenic angles (thoracic inlet to adrenals).
• Acquisition: Volumetric helical, thin collimation (0.6-1 mm).
• Tube voltage/current: 100-120 kVp (80-100 kVp for pediatric/slim patients); automatic tube current modulation (reference 40-200 mAs).
• Pitch/rotation: 1-1.5; 0.5 s.
• Reconstruction: High-spatial-resolution lung kernel (B60-B80), 1-1.5 mm axial slices; soft-tissue kernel for mediastinum; multiplanar reformats (coronal/sagittal), maximum/minimum intensity projections (MIP/minIP).
• Radiation dose: Standard 3-8 mSv; iterative reconstruction (IR) or deep learning reduces to 1-3 mSv [9].

HRCT variant: Interspaced thin slices (1-2 mm every 10-20 mm) for interstitial detail with lower dose.

Contrast-Enhanced Chest CT (CECT)

Indicated for suspected complications (abscess vs necrosis, empyema, vascular involvement), non-resolving pneumonia, or pulmonary embolism suspicion.

• Contrast: 80-120 mL non-ionic iodinated (300-350 mgI/mL), 3-4 mL/s injection.
• Timing: Portal venous phase (55-70 s) for parenchymal enhancement; arterial phase for PE protocol.
• Dual-energy CT (DECT): Optional for iodine mapping/perfusion defects in Long COVID or vascular sequelae.

Low-Dose and Ultra-Low-Dose Protocols

Essential for follow-up, pediatric, or immunocompromised patients. Ultra-low-dose CT (ULDCT, <1 mSv, often 0.2-0.5 mSv) with model-based iterative reconstruction (MBIR) or deep learning denoising achieves 98-99% diagnostic agreement for GGO, consolidation, and viral patterns compared to standard-dose [9,10]. 2025 multisociety consensus recommends low-dose (1-3 mSv) for post-COVID residual abnormality assessment; ultra-low-dose (<0.5 mSv) not routinely advised for subtle GGO evaluation due to potential noise [11].

Supplemental techniques: Expiratory scans for air trapping; prone positioning for dependent changes.

Chest CT Patterns in Pneumonia

Bacterial Pneumonia

Classically presents with lobar or segmental consolidation, often homogeneous with air bronchograms. S. pneumoniae: Single-lobe involvement. Klebsiella: Bulging fissure sign from voluminous exudate. Necrotizing pathogens (S. aureus, anaerobes): Cavitation, abscess formation. Tree-in-bud opacities indicate bronchiolar spread; parapneumonic effusions/empyema common [3].

Viral Pneumonia

Multifocal, bilateral GGO predominant (peripheral/peribronchovascular); crazy-paving frequent. Consolidation secondary. Influenza: Patchy peribronchovascular. Adenovirus: Lobar consolidation mimicking bacterial. Immunocompromised (CMV, VZV): Nodular GGO with halos. Tree-in-bud in viral bronchiolitis [12].

Fungal Pneumonia

Varies by immune status. Angioinvasive aspergillosis (neutropenic): Nodules with halo sign (hemorrhage). Recovery phase: Air crescent sign. Pneumocystis jirovecii: Diffuse bilateral GGO with crazy-paving/cysts. Endemic fungi (histoplasmosis): Miliary nodules, cavitation. Mucormycosis: Reverse halo in immunocompromised [13].

COVID-19 Pneumonia on Chest CT: Acute Patterns, 2026 Variants, and Long COVID Sequelae

Acute COVID-19 Patterns

Bilateral, peripheral/multifocal round/oval GGO predominant; basal/peripheral distribution. Progression: Crazy-paving, consolidation (often organizing), linear/reticular opacities, vascular thickening, reverse halo. Peak severity ~10-14 days post-onset [4,14].

2026 SARS-CoV-2 Variants

Omicron subvariants dominate (XFG ~53%, XFG.14.1 ~16%, others); increased transmissibility but reduced virulence. Systematic reviews/meta-analyses (2025) show Omicron-associated pneumonia has more atypical/non-typical features (peribronchovascular, upper-lobe predominance) vs. Delta/earlier strains; less consolidation, lower CT severity scores, and more normal scans (37% Omicron vs. 15% Delta in some cohorts). No major novel patterns; overlaps with prior Omicron waves [5,6,15,16].

Long COVID Pulmonary Sequelae

Post-acute sequelae affect 10-30% of survivors with persistent respiratory symptoms >12 weeks. Chest CT abnormalities in 30-70% at 6-12 months (higher post-severe disease): GGO decline over time (32% at 6 months → 20% at 36 months); fibrosis/reticulation/traction bronchiectasis stable/persistent (27-47% up to 36 months) [17,18]. Non-fibrotic changes (bands, heterogeneous attenuation) regress more readily. 2025 consensus recommends CT for persistent/worsening symptoms ≥3 months (lasting ≥2 months, no alternative cause); use “post-COVID-19 residual lung abnormality” terminology to avoid conflating with idiopathic interstitial lung disease; prefer low-dose protocols [11,19].

Long COVID Cardiac Effects

Elevated risk of major adverse cardiovascular events (MACE: MI, stroke, heart failure, arrhythmia) up to 2-3 years post-infection, even in mild cases. Mechanisms: Persistent inflammation, endothelial dysfunction, accelerated atherosclerosis, microvascular injury [20,21]. Symptoms (palpitations, chest pain, dyspnea) overlap pulmonary sequelae.

Advanced imaging:

• PET/MRI: Detects persistent inflammation; 2025 large cohort shows abnormalities in 57%: myocarditis-like (24%), pericarditis (22%), periannular uptake (11%), vascular uptake (aortic/pulmonary, 30%). No uptake in controls [22,23].
• Chest CT role: Incidental findings (pericardial effusion, cardiomegaly, coronary calcification). DECT assesses pulmonary perfusion defects linked to cardiopulmonary strain.

Multimodal imaging (MRI/PET gold-standard for inflammation) recommended for symptomatic patients; abnormal findings may predict future cardiac/pulmonary disease warranting monitoring [24].

Pediatric Pneumonia on Chest CT

Pediatric patterns differ: Viral (RSV, parainfluenza, adenovirus) predominant in younger children—bronchial wall thickening, centrilobular nodules, tree-in-bud, multifocal GGO. Bacterial: Lobar consolidation, frequent complications (necrotizing, abscess, pneumatocele). Mycoplasma: Interstitial/reticular patterns.

CT use limited due to radiation sensitivity; reserved for complicated, non-resolving, or immunocompromised cases. Low-dose/ULDCT essential; LUS often first-line [7,25].

Complications of Pneumonia on Chest CT

• Necrotizing pneumonia/abscess: Non-enhancing areas, cavitation, air-fluid levels within consolidation.
• Empyema: Lenticular pleural collection, split pleura sign (enhancing visceral/parietal pleura), loculations.
• Bronchopleural fistula: Persistent pneumothorax with cavity-pleural communication.

Contrast enhancement crucial for differentiation; higher incidence in pediatric bacterial or severe viral/necrotic cases [3,26].

Differential Diagnosis and Pattern-Based Approach

CT patterns overlap; clinical/microbiological correlation essential.

Sensitivity and Specificity of Chest CT

Chest CT sensitivity for pneumonia detection approaches 95-99%, far exceeding CXR [3]. For COVID-19: Pooled sensitivity 87-97%, specificity 46-70% vs RT-PCR (overlap with other viral pneumonias) [14,28]. ULDCT maintains high performance for viral patterns [9]. High negative predictive value aids exclusion of disease [29].

Recent Advances and Future Directions

• ULDCT with deep learning reconstruction achieves near-standard diagnostic quality at minimal dose [10].
• AI: Automated detection (>95% accuracy), severity quantification, pattern classification (variant-invariant) [27].
• Quantitative CT: Lung volume, fibrosis extent scoring.
• Hybrid imaging: PET/CT or PET/MRI for inflammation in Long COVID.
• Future: AI-driven prognostic models, biomarker integration, personalized follow-up.

Discussion and Conclusion

Chest CT transforms pneumonia diagnosis with unparalleled detail and high sensitivity, revealing etiology-guiding patterns while enabling complication detection and severity assessment. COVID-19 acute imaging remains characteristic, with 2026 Omicron variants showing milder, more atypical features. Long COVID highlights persistent pulmonary residuals (declining GGO, stable fibrosis) and cardiac inflammation (PET/MRI abnormalities in >50%), underscoring the need for multimodal follow-up and risk stratification.

Judicious CT use (low-dose protocols), clinical integration, and radiation stewardship remain paramount. Future advances in AI and hybrid imaging promise enhanced precision and outcomes.

References 

1. Franquet, T. (2001). Imaging of pneumonia: Trends and algorithms. European Respiratory Journal, 18(1), 196–208. https://doi.org/10.1183/09031936.01.00213501
2. Walker, C. M., Abbott, G. F., Greene, R. E., Sly, P. D., Ketai, L. H., & Marchiori, E. (2014). Imaging pulmonary infection: Classic signs and patterns. American Journal of Roentgenology, 202(3), 479–492. https://doi.org/10.2214/AJR.13.11463
3. Walker, C. M., Abbott, G. F., Greene, R. E., Sly, P. D., Ketai, L. H., & Marchiori, E. (2014). Imaging pulmonary infection: Classic signs and patterns. American Journal of Roentgenology, 202(3), 479–492. https://doi.org/10.2214/AJR.13.11463
4. Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., Cui, J., Xu, W., Yang, Y., Fayad, Z. A., Jacobi, A., Li, K., Li, S., & Shan, H. (2020). CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology, 295(1), 202–207. https://doi.org/10.1148/radiol.2020200230
5. Han, Y., Wang, Z., Li, X., & Zhong, Z. (2025). Differences in chest imaging between Omicron and non–Omicron coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. BMC Infectious Diseases, 25(1), 631. https://doi.org/10.1186/s12879-025-11032-z
6. Xu, W., Zhao, J., Wang, T., Lai, J., Wang, J., Jiang, F., Wang, C., & Fu, G. (2026). Clinical and CT image features for survival prediction in severe pneumonia during the SARS-CoV-2 Omicron wave. Frontiers in Medicine, 12, Article 1663710. https://doi.org/10.3389/fmed.2025.1663710
7. Andronikou, S., Lambert, E., Halton, J., Hilder, L., & Crumley, I. (2024). Imaging of acute complications of community-acquired pneumonia in children. Children, 11(1), 122. https://doi.org/10.3390/children11010122
8. Rawat, M., Saade, C., Rawat, U., Ahlawat, S., Obeid, R., & Ghosn, Y. (2021). Radiation dose reduction considerations and imaging patterns of ground glass opacities in coronavirus: Risk of over exposure in computed tomography. La Radiologia Medica, 126(2), 307–311. https://doi.org/10.1007/s11547-020-01272-9
9. Dangis, A., Gieraerts, C., De Bruecker, Y., Janssen, L., Valgaeren, H., Obbels, D., Gillis, M., Van Cauteren, T., Verbeke, P., & De Brucker, N. (2021). Ultra-low-dose chest CT performance for the detection of viral pneumonia patterns during the COVID-19 outbreak period: A monocentric, retrospective, observational cohort study. Quantitative Imaging in Medicine and Surgery, 11(7), 2976–2987. https://doi.org/10.21037/qims-20-1336
10. Slasky, B. S., & Walker, C. M. (2025). Denoised ultra-low-dose chest CT to assess pneumonia in immunocompromised patients. Radiology: Cardiothoracic Imaging, 7(2), e240189. https://doi.org/10.1148/ryct.240189
11. Larici, R., et al. (2025). Best practice: International multisociety consensus statement for post–COVID-19 residual abnormalities on chest CT scans. Radiology. https://doi.org/10.1148/radiol.243374
12. Franquet, T., Jeong, Y. J., Lam, K. S., Chung, M. J., Lee, K. S., Goo, J. M., & Müller, N. L. (2018). Radiographic and CT features of viral pneumonia. RadioGraphics, 38(3), 719–739. https://doi.org/10.1148/rg.2018170048
13. Marchiori, E., Zanetti, G., Hochhegger, B., & Irion, K. L. (2019). Pulmonary invasive fungal disease and bacterial pneumonia: Distinctive CT patterns in immunocompromised patients. American Journal of Translational Research, 11(7), 4239–4247. https://pmc.ncbi.nlm.nih.gov/articles/PMC6684894
14. Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., Tao, Q., Sun, Z., & Xia, L. (2020). Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology, 296(2), E32–E40. https://doi.org/10.1148/radiol.2020200642
15. Han, Y., et al. (2025). Differences in chest imaging between Omicron and non–Omicron coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. BMC Infectious Diseases, 25(1), 631. https://doi.org/10.1186/s12879-025-11032-z
16. Xu, W., et al. (2026). Clinical and CT image features for survival prediction in severe pneumonia during the SARS-CoV-2 Omicron wave. Frontiers in Medicine, 12, Article 1663710. https://doi.org/10.3389/fmed.2025.1663710
17. Cavalcanti, L., et al. (2026). Long-term pulmonary function and radiologic abnormalities up to 3 years after COVID-19: A systematic review and meta-analysis. Korean Journal of Radiology. https://doi.org/10.3348/kjr.2025.1272
18. Mount Sinai Reports. (2025). Persistent cardiovascular and pulmonary abnormalities in Long COVID patients. https://reports.mountsinai.org/article/card2026-long-covid
19. Larici, R., et al. (2025). Best practice: International multisociety consensus statement for post–COVID-19 residual abnormalities on chest CT scans. Radiology. https://doi.org/10.1148/radiol.243374
20. Bell, L. C., et al. (2025). Persistent cardiovascular and pulmonary abnormalities in Long COVID patients. Mount Sinai Reports.
21. Xie, Y., et al. (2025). Long-term cardiovascular outcomes following COVID-19. Nature Medicine.
22. Trivieri, M. G., et al. (2025). Prevalence of persistent cardiovascular and pulmonary abnormalities on PET/MRI and DECT imaging in long COVID patients. Journal of Nuclear Medicine, 66(7), 1126-1134. https://doi.org/10.2967/jnumed.124.268980
23. Mount Sinai. (2025). Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT.
24. SNMMI. (2025). Abnormal Long COVID PET/MR findings linked to future cardiac and pulmonary diseases.
25. Andronikou, S., et al. (2024). Imaging of acute complications of community-acquired pneumonia in children. Children, 11(1), 122. https://doi.org/10.3390/children11010122
26. Hogan, M. J., & Coley, B. D. (2008). Interventional radiology treatment of empyema and lung abscesses. Pediatric Respiratory Reviews, 9(2), 122–129. https://doi.org/10.1016/j.prrv.2008.01.004
27. Slasky, B. S., & Walker, C. M. (2025). Denoised ultra-low-dose chest CT to assess pneumonia in immunocompromised patients. Radiology: Cardiothoracic Imaging, 7(2), e240189. https://doi.org/10.1148/ryct.240189
28. Islam, N., Ebrahimzadeh, S., Salameh, J. P., Kazi, S., Fabiano, N., Treanor, L., Absi, M., Hallgrimson, Z., Leeflang, M. M. G., Hooft, L., van der Pol, C. B., Prager, R., McInnes, M. D. F., & Moher, D. (2021). Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database of Systematic Reviews, 3(3), CD013639. https://doi.org/10.1002/14651858.CD013639.pub4
29. Xu, B., Xing, Y., Peng, J., Zheng, Z., Tang, W., Sun, Y., Xu, C., & Peng, F. (2020). Chest CT for detecting COVID-19: A systematic review and meta-analysis of diagnostic accuracy. European Radiology, 30(10), 5720–5727. https://doi.org/10.1007/s00330-020-06934-2